Skip to main content
S&P 5007,688.62+1.58%DOW53,356.12+3.03%NASDAQ25,736.51+1.44%BTC$80,512.00+3.73%ETH$2,425.60+6.33%GOLD$4,073.90+0.02%OIL$88.26+0.16%
Smart Investors Daily
SID Premium
AG

NASDAQ · AGMB

AgomAb Therapeutics N.V. American Depositary Shares

Healthcare · Biotechnology

$6.85

Up+$0.00 (+0.00%)

Updated Nov 4, 2026, 11:46 PM

SID Score

2.8/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
400.5K
P/E ratio
-10.62
Dividend yield
0.00%
52-week range
$6.52 – $17.82
Volume
40.35K
Avg. volume
382.73K

Price performance · AGMB

AGMB price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Nov 3, 2026

AGMB closed at $6.85 after 21 trading sessions, down 22.51% for the selected period.

Last close
$6.85
Period change
-22.51%
Period low
$6.72
Period high
$9.26
Daily close
View OHLC price history
AGMB OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Nov 3, 2026$6.67$7.155$6.67$6.8540.35K
Nov 2, 2026$7.57$8.1108$6.52$6.72105.63K
Oct 30, 2026$7.00$7.955$6.61$7.49197.83K
Oct 29, 2026$7.98$8.292$7.45$7.95575.39K
Oct 28, 2026$8.37$8.37$7.70$7.96105.6K
Oct 27, 2026$8.60$8.60$7.88$8.4089.8K
Oct 26, 2026$9.10$9.33$8.44$8.5773.85K
Oct 23, 2026$9.15$9.184$8.5663$9.0552.22K
Oct 22, 2026$9.15$9.44$8.90$9.2684.32K
Oct 21, 2026$8.74$9.22$8.74$9.1146.84K
Oct 20, 2026$8.24$8.97$8.21$8.7335.3K
Oct 19, 2026$8.28$8.61$8.16$8.2340.38K
Oct 16, 2026$8.21$8.53$7.92$8.2878.13K
Oct 15, 2026$8.56$8.86$8.15$8.3397.72K
Oct 14, 2026$8.80$9.08$8.51$8.6957.7K
Oct 13, 2026$9.05$9.35$8.725$8.8159.38K
Oct 12, 2026$9.18$9.65$9.045$9.0962.28K
Oct 9, 2026$9.36$9.49$8.915$9.08102.31K
Oct 8, 2026$8.88$9.45$8.56$9.22225.19K
Oct 7, 2026$8.95$9.3495$8.675$8.80104.93K
Oct 6, 2026$8.77$8.965$8.395$8.84103.92K

Latest AGMB news

The latest Smart Investors Daily articles mentioning AGMB.

Stock researchCompany · Overview

AGMB research

Overview

Company profile and research snapshot.

Company profile

AgomAb Therapeutics NV is a clinical-stage biopharmaceutical company focused on developing novel disease-modifying therapies for immunology and inflammatory diseases, with an initial focus on chronic fibrotic indications with high unmet medical need. Its product candidates are designed to target established pathways and utilize validated modalities, with a focus on addressing limitations associated with prior treatment approaches. The company's pipeline includes small molecule and antibody product candidates aimed at targets associated with fibrotic diseases. Key candidates include Ontunisertib (AGMB-129) and AGMB-447.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
—
Implied upside
—
Analysts
—
AGMB recent ratings
DateFirmRatingTarget
Aug 25, 2026Piper SandlerOverweight—
Aug 19, 2026Cantor FitzgeraldOverweight—
Jul 23, 2026B. Riley SecuritiesBuy—
Jun 22, 2026HC Wainwright & Co.Buy—
Mar 3, 2026JP MorganOverweight—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 13, 2026

Agomab Announces First Patient Dosed in Global NOV-ERA Phase 2b Study of Ontunisertib in Fibrostenosing Crohn's Disease

-- NOV-ERA is designed to assess the efficacy and safety of ontunisertib in approximately 320 patients with symptomatic Fibrostenosing Crohn's disease (FSCD) -- -- Global, randomized, placebo-controlled, dose-ranging study to evaluate three dose levels of ontunisertib, with endoscopic passability at Week 24 as primary endpoint -- -- Study initiation represents an important milestone in the development of ontunisertib as a potential first targeted anti-fibrotic treatment for FSCD -- Antwerp, Belg

Yahoo · Oct 8, 2026

Agomab to Present STENOVA Open-Label Extension Data of Ontunisertib at UEG Week 2026 and Host Scientific Symposium on Fibro-Inflammation

-- Open-Label Extension (OLE) Data of STENOVA Phase 2a study with ontunisertib in Fibrostenosing Crohn’s disease (FSCD) selected for oral presentation at UEG Week 2026 -- -- Results support initiation of global NOV-ERA Phase 2b study in FSCD -- -- Agomab-sponsored symposium to discuss the importance of targeting fibro-inflammation in inflammatory bowel disease (IBD) -- Antwerp, Belgium, October 8, 2026 – Agomab Therapeutics NV (‘Agomab’) a clinical-stage biopharmaceutical company focused on fibr

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By